Alessandra Tedeschi, MD
DISCLAIMER
The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
SUMMARY
This ongoing phase 1/1b study evaluated investigational sonrotoclax monotherapy or combination therapies in patients with mature B-cell malignancies. This analysis reported the updated safety and efficacy results for patients with relapsed/refractory marginal zone lymphoma (R/R MZL) from the study. As of the May 18, 2026, data cutoff, 24 patients had received sonrotoclax across four dose levels (40 mg, n=1; 160 mg, n=2; 320 mg, n=10; 640 mg, n=11, once daily), with a median follow-up of 30.2 months (range, 3.5-60.5 months). The most common (≥20%) all-grade treatment-emergent adverse events (TEAEs) were pyrexia (46%), anemia (29%), nausea (29%), neutropenia (25%), constipation (25%), fatigue (25%), headache (25%), cough (21%), and diarrhea (21%). Grade ≥3 TEAEs (≥10%) included anemia (17%), neutropenia (17%), and pneumonia (13%). No cases of clinical tumor lysis syndrome were reported. Laboratory tumor lysis syndrome was observed in 2 patients in the 640-mg cohort during ramp-up; in both cases, it resolved within 24 hours without sequelae or dose modification. Across all dose levels (n=24), overall response rate (ORR) was 50%, and the complete response rate (CRR) was 17%; in the 640-mg cohort (n=11), ORR was 73% and the CRR was 36%. Median progression-free survival (PFS) in the 640-mg cohort (n=11) was 27.1 months (95% CI, 5.6 months-not estimable; 24-month PFS rate was 55% [95% CI, 23%-78%]), and median duration of response was not reached.
ClinicalTrials.gov ID: NCT04277637
Haitao Wang, PhD
Alvaro Alencar, MD
Nakhle S. Saba, MD
Are you a returning user?
LOGINFor new users, please select your country/region
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed